CAR T-cell therapy has transformed cancer care by offering a highly personalized way to fight tumors. By reprogramming a patient’s own immune cells to recognize and attack cancer, this approach can deliver long-lasting remissions. Yet, not all patients benefit equally—and scientists have been searching for answers.

A new study from Rutgers University, published in Cell Reports, reveals a crucial factor behind this variability: the pre-existing condition of the patient’s immune cells—specifically, whether they have entered a state known as cellular senescence.

When Immune Cells Lose Their Edge

The therapy relies on CD8+ T cells—specialized cells that kill infected or cancerous cells. However, many patients’ T cells are already compromised before treatment begins. The study found that a significant portion of these cells exist in a senescent state. These aging cells no longer divide effectively, struggle to move through the body, and have reduced ability to destroy cancer cells. Although they remain in circulation, they release inflammatory signals that can disrupt immune function.

Figure 1. Notion pages.

Not Just About Age

Interestingly, senescence isn’t solely tied to aging. While older individuals tend to have a higher proportion of senescent T cells, the underlying molecular program appears consistent across age groups. This suggests that the transition into senescence is a built-in biological process rather than simply a result of getting older. In some patients, up to 80% of T cells showed signs of senescence—dramatically limiting the effectiveness of therapies that depend on these cells. Figure 1 shows notion pages.

Inside the Biology of Senescence

To understand what drives this dysfunction, researchers analyzed gene expression and chromatin structure in both healthy and senescent T cells. They identified a core network of transcription factors that act as molecular switches, controlling whether a cell becomes active or enters senescence.

Encouragingly, early experiments showed that targeting these regulators—through chemical or genetic approaches—could partially reverse the senescent state. Some treated cells began to regain features of healthy, functional T cells, hinting at ways to improve therapy outcomes.

A Predictor of Treatment Success

The findings also have immediate clinical relevance. By examining data from lymphoma patients, researchers found that those with higher levels of senescent T cells were far less likely to respond to CAR T-cell therapy. In contrast, patients with more “youthful” immune cells experienced better outcomes [1]. This suggests that screening for senescence before treatment could help predict which patients are most likely to benefit—and guide alternative strategies for those who are not.

Toward Smarter, Personalized Therapies

The research team, led by Ricardo Iván Martínez-Zamudio, is now exploring how to integrate senescence profiling into clinical workflows. Future therapies may not only target the cancer itself but also optimize the quality of the immune cells used in treatment.

Implications Beyond Cancer

The impact of this discovery extends beyond oncology. Senescent immune cells contribute to “inflammaging,” a chronic inflammatory state linked to diseases such as autoimmune disorders and cardiovascular conditions. Similar senescence patterns were observed in patients with lupus, suggesting a broader role in immune dysfunction.

A New Direction for Immunotherapy

This study challenges the idea that immune aging is inevitable and irreversible. Instead, it points to senescence as a programmable—and potentially reversible—state.

By learning how to rejuvenate or replace dysfunctional immune cells, scientists may unlock more consistent and effective cancer treatments. Ultimately, this work marks an important step toward precision immunotherapy—where success depends not just on targeting tumors, but on harnessing the full potential of the patient’s immune system.

Reference:

1. https://cyberinsider.com/notion-pages-have-leaked-user-data-via-an-unauthenticated-api-since-2022/

Cite this article:

Keerthana S (2026), Why Some Cell Therapies Fall Short in Cancer Treatment, AnaTechMaz, pp.188